3 0 0 0 OA MicroRNA-302 switch to identify and eliminate undifferentiated human pluripotent stem cells.
- 著者
- Parr Callum J C Katayama Shota Miki Kenji Kuang Yi Yoshida Yoshinori Morizane Asuka Takahashi Jun Yamanaka Shinya Saito Hirohide
- 出版者
- Springer Nature
- 雑誌
- Scientific reports (ISSN:20452322)
- 巻号頁・発行日
- vol.6, 2016-09-09
- 被引用文献数
- 77
iPS細胞を選択的に識別・分離・除去できるしくみを合成RNAを用いて構築. 京都大学プレスリリース. 2016-09-09.
- 著者
- Nakagawa Masato Taniguchi Yukimasa Senda Sho Takizawa Nanako Ichisaka Tomoko Asano Kanako Morizane Asuka Doi Daisuke Takahashi Jun Nishizawa Masatoshi Yoshida Yoshinori Toyoda Taro Osafune Kenji Sekiguchi Kiyotoshi Yamanaka Shinya
- 出版者
- Nature Publishing Group
- 雑誌
- Scientific Reports (ISSN:20452322)
- 巻号頁・発行日
- vol.4, 2014-01-08
- 被引用文献数
- 481
細胞移植に適した新しいヒトiPS細胞の樹立・維持培養法を確立. 京都大学プレスリリース. 2014-01-08.
- 著者
- Yoshida Yoshinori Takahashi Kazutoshi Okita Keisuke Ichisaka Tomoko Yamanaka Shinya
- 出版者
- Elsevier
- 雑誌
- Cell Stem Cell (ISSN:19345909)
- 巻号頁・発行日
- vol.5, no.3, pp.237-241, 2009-08
- 被引用文献数
- 4 613
低酸素濃度培養によるiPS細胞樹立効率の改善 -効率的な樹立方法開発に貢献する知見をCell Stem Cellに報告-. 京都大学プレスリリース. 2009-08-28. http://www.kyoto-u.ac.jp/ja/news_data/h/h1/news6/2009/090828_2.htm
1 0 0 0 OA iPS cells: A source of cardiac regeneration
- 著者
- Yoshida Yoshinori Yamanaka Shinya
- 出版者
- Elsevier
- 雑誌
- Journal of Molecular and Cellular Cardiology (ISSN:00222828)
- 巻号頁・発行日
- vol.50, no.2, pp.327-332, 2011-02
- 被引用文献数
- 123
For the treatment of heart failure, a new strategy to improve cardiac function and inhibit cardiac remodeling needs to be established. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are pluripotent cells that can differentiate into cell types from all three germ layers both in vitro and in vivo. The therapeutic effect of ES/iPS cell-derived progeny was reported in animal model. Mouse and human somatic cells can be reprogrammed to induced pluripotent stem cells (iPSCs) by the transduction of four transcription factors, Oct 3/4, Sox2, Klf4, and c-Myc. However, the low induction efficiency hinders the clinical application of iPS technology, and efforts have been made to improve the reprogramming efficiency. There are variations in the characteristics in ES/iPS cell lines, and the further understanding is necessary for the applications of ES/iPS cell technology. Some improvements were also made in the methods to induce cardiomyocytes from ES/iPS cells efficiently. This review article is focused on generation of iPS cells, cardiomyocyte differentiation from ES/iPS cells, and transplantation of derived cardiomyocytes.This article is part of a special issue entitled, "Cardiovascular Stem Cells Revisited".